Chandra Adams - Oct 27, 2022 Form 3 Insider Report for Surface Oncology, Inc. (SURF)

Role
Deputy GC
Signature
/s/ Jessica Fees, as Attorney-in-Fact
Stock symbol
SURF
Transactions as of
Oct 27, 2022
Transactions value $
$0
Form type
3
Date filed
11/3/2022, 08:00 PM
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SURF Common Stock 34.8K Oct 27, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SURF Stock Option (Right to Buy) Oct 27, 2022 Common Stock 16K $4.77 Direct F2
holding SURF Stock Option (Right to Buy) Oct 27, 2022 Common Stock 13.8K $3.18 Direct F3
holding SURF Stock Option (Right to Buy) Oct 27, 2022 Common Stock 40K $9.02 Direct F4
holding SURF Stock Option (Right to Buy) Oct 27, 2022 Common Stock 41K $3.64 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The 21,000 RSUs underlying this award vest as follows: 40% on August 1, 2022 and the remaining 60% on August 1, 2023, so long as the reporting person remains an employee or other service provider of the Issuer on such date.
F2 25% of this option vested and became exercisable on April 24, 2020, and the remainder of the option vests in equal monthly installments over the following three-year period, so that all of the underlying shares shall be vested on April 24, 2023, so long as the reporting person remains an employee or other service provider of the Issuer on such dates.
F3 This option vests in equal monthly installments over four years following January 21, 2020, so that all of the underlying shares shall be vested on January 21, 2024, so long as the reporting person remains an employee or other service provider of the Issuer on such dates.
F4 This option vests in equal monthly installments over four years following February 9, 2021, so that all of the underlying shares shall be vested on February 9, 2025, so long as the reporting person remains an employee or other service provider of the Issuer on such dates.
F5 This option vests in equal monthly installments over four years following February 8, 2022, so that all of the underlying shares shall be vested on February 8, 2026, so long as the reporting person remains an employee or other service provider of the Issuer on such dates.

Remarks:

Exhibit 24 - Power of Attorney